Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines


Journal Article

© National Comprehensive Cancer Network, Inc. 2016, All rights reserved. These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.

Duke Authors

Cited Authors

  • Clark, PE; Spiess, PE; Agarwal, N; Bangs, R; Boorjian, SA; Buyyounouski, MK; Efstathiou, JA; Flaig, TW; Friedlander, T; Greenberg, RE; Guru, KA; Hahn, N; Herr, HW; Hoimes, C; Inman, BA; Kader, AK; Kibel, AS; Kuzel, TM; Lele, SM; Meeks, JJ; Michalski, J; Montgomery, JS; Pagliaro, LC; Pal, SK; Patterson, A; Petrylak, D; Plimack, ER; Pohar, KS; Porter, MP; Sexton, WJ; Siefker-Radtke, AO; Sonpavde, G; Tward, J; Wile, G; Dwyer, MA; Smith, C

Published Date

  • October 1, 2016

Published In

Volume / Issue

  • 14 / 10

Start / End Page

  • 1213 - 1224

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

International Standard Serial Number (ISSN)

  • 1540-1405

Citation Source

  • Scopus